SOLUTION OF SOCIAL PROBLEMS IN
MANAGEMENT AND ECONOMY
International scientific-online conference
129
MIGRAINE: CAUSES AND TREATMENT METHODS
Tohtaraliyeva Sevinch
University of Business and Science
Student of group 23_01, 2nd year, the rapeutic work direction
Usmonova Feruza Nematjonovna
Scientific advisor:
https://doi.org/10.5281/zenodo.15558916
Abstract:
Migraine is a prevalent neurological disorder characterized by
recurrent, debilitating headaches and a spectrum of sensory, autonomic, and
cognitive symptoms, affecting 15-20% of the global population. Its complex
etiology involves genetic predisposition, environmental triggers, and
neurovascular mechanisms, including cortical spreading depression,
trigeminovascular activation, and serotonin dysregulation. Recent advances
have highlighted the role of calcitonin gene-related peptide (CGRP) and the gut-
brain axis in pathogenesis, driving the development of targeted therapies such
as CGRP monoclonal antibodies and neuromodulation devices. This article
provides a comprehensive overview of migraine causes, integrating genetic,
neurobiological, and environmental perspectives, and evaluates current and
emerging treatment strategies, including pharmacological, non-pharmacological,
and lifestyle interventions. Despite therapeutic progress, challenges such as
treatment access, cost barriers, and disease heterogeneity persist. The article
underscores the need for personalized medicine, multidisciplinary care, and
global health initiatives to alleviate the substantial burden of migraines.
Keywords
: Migraine, headache, trigeminovascular system, cortical
spreading depression, CGRP, serotonin, neuromodulation, monoclonal
antibodies, gut-brain axis, personalized medicine, neuroinflammation,
preventive treatment.
Migraine is a chronic and debilitating neurological disorder characterized
by recurrent, often excruciating headaches accompanied by a diverse array of
sensory, autonomic, cognitive, and psychological symptoms. Affecting
approximately 15-20% of the global population, with a three-fold higher
prevalence in women due to hormonal influences, migraines impose a profound
burden on individuals, healthcare systems, and economies, contributing to
significant disability, lost productivity, and healthcare costs. The disorder’s
complexity arises from its multifactorial etiology, encompassing genetic
predisposition, environmental triggers, and intricate neurovascular,
neuroinflammatory, and neuroendocrine mechanisms. Recent advances in
neuroimaging, molecular biology, systems neuroscience, and therapeutic
SOLUTION OF SOCIAL PROBLEMS IN
MANAGEMENT AND ECONOMY
International scientific-online conference
130
innovation have significantly deepened our understanding of migraines, yet
challenges in achieving universal treatment efficacy and equitable access to care
persist. This article provides an exhaustive exploration of the causes of
migraines and the evolving landscape of treatment methods, synthesizing
established knowledge with cutting-edge research to illuminate this
multifaceted condition and its comprehensive management.
The pathogenesis of migraines is driven by a dynamic interplay of genetic,
environmental, and neurobiological factors. Genetic studies have been pivotal in
elucidating the hereditary basis of migraines, particularly through the
identification of mutations associated with familial hemiplegic migraine (FHM),
a rare monogenic subtype. Mutations in genes such as CACNA1A (encoding a
voltage-gated calcium channel), ATP1A2 (encoding a sodium-potassium
ATPase), and SCN1A (encoding a sodium channel) disrupt ion homeostasis and
synaptic transmission, leading to heightened cortical excitability. These genetic
alterations provide a mechanistic basis for the hyperexcitable brain state
observed in migraineurs. Beyond FHM, genome-wide association studies
(GWAS) have identified over 38 genetic loci associated with common migraine
forms, implicating pathways involved in vascular function, neuronal signaling,
pain modulation, and glutamate homeostasis. These findings suggest a polygenic
architecture for migraines, with cumulative genetic variants contributing to
individual susceptibility and phenotypic variability.
Environmental triggers significantly modulate migraine onset, interacting
with genetic predispositions to create a highly individualized disease profile.
Common triggers include psychological stress, sleep disturbances (e.g.,
insomnia, sleep apnea, or excessive sleep), dietary factors (e.g., caffeine, alcohol,
chocolate, aged cheeses, monosodium glutamate, or aspartame), sensory stimuli
(e.g., bright lights, loud noises, strong odors, or visual patterns), and
meteorological changes (e.g., barometric pressure shifts). Hormonal
fluctuations, particularly in estrogen levels, are a critical trigger in women, with
migraines frequently correlating with menstrual cycles, pregnancy, postpartum
periods, or menopausal transitions. This hormonal link is supported by evidence
of altered estrogen receptor expression in brain regions such as the
hypothalamus, amygdala, and prefrontal cortex, which are involved in pain
processing, emotional regulation, and autonomic control. The variability of
triggers underscores the importance of personalized trigger identification
through patient diaries and clinical assessments, which are critical for effective
management.
SOLUTION OF SOCIAL PROBLEMS IN
MANAGEMENT AND ECONOMY
International scientific-online conference
131
At the neurobiological level, migraines arise from a complex cascade of
events centered on the trigeminovascular system, a critical interface between
the peripheral nervous system and intracranial structures. Activation of
trigeminal nerve afferents triggers the release of vasoactive neuropeptides,
notably calcitonin gene-related peptide (CGRP), substance P, and neurokinin A,
which induce vasodilation and neurogenic inflammation in the meninges. This
process is thought to generate the characteristic throbbing, unilateral pain of
migraines, often exacerbated by physical activity. Cortical spreading depression
(CSD), a slowly propagating wave of neuronal and glial depolarization followed
by prolonged suppression, is a key mechanism underlying migraine aura,
experienced by approximately 25-30% of patients. CSD disrupts cortical
homeostasis, leading to transient neurological symptoms such as visual
disturbances (e.g., scintillating scotomas, zigzag lines, or tunnel vision), sensory
changes (e.g., paresthesia or numbness), motor deficits, or language difficulties
(e.g., aphasia). Functional neuroimaging studies, including functional MRI,
positron emission tomography, and magnetoencephalography, have revealed
that CSD alters connectivity in pain-processing networks, including the
thalamus, insula, anterior cingulate cortex, periaqueductal gray, and
rostroventromedial medulla, amplifying nociceptive signaling and contributing
to central sensitization in chronic migraineurs.
Serotonin dysregulation is a cornerstone of migraine pathophysiology.
Reduced serotonin levels during attacks are associated with increased pain
sensitivity, vascular reactivity, and trigeminal activation, while serotonin
receptor agonists, such as triptans, effectively abort attacks by targeting 5-
HT1B/1D receptors. The hypothalamus, activated during the premonitory phase
of migraines (characterized by symptoms such as yawning, fatigue, irritability,
mood changes, or food cravings), plays a pivotal role in attack initiation, likely
through its regulation of autonomic, circadian, and neuroendocrine functions.
Emerging evidence also implicates the gut-brain axis in migraine pathogenesis.
Dysbiosis of the gut microbiota has been linked to increased systemic
inflammation, potentially via elevated levels of pro-inflammatory cytokines (e.g.,
IL-1β, IL-6, TNF-α) or altered production of short-chain fatty acids, which
influence neuronal signaling and blood-brain barrier integrity. This connection
suggests that dietary interventions, probiotics, or prebiotics may serve as novel
therapeutic strategies. Additionally, dysregulation of central pain modulation
pathways, including the brainstem’s descending inhibitory systems and the
SOLUTION OF SOCIAL PROBLEMS IN
MANAGEMENT AND ECONOMY
International scientific-online conference
132
rostroventromedial medulla, contributes to the chronicity of migraines,
particularly in patients with frequent attacks or medication overuse headache.
Neuroinflammatory processes are increasingly recognized as critical
contributors to migraine pathophysiology. Microglial activation in the brain and
spinal cord releases pro-inflammatory mediators, such as interleukins and
chemokines, exacerbating pain signaling and neuronal excitability. Mast cells in
the meninges, activated by stress, allergens, or other triggers, release histamine,
prostaglandins, and other inflammatory molecules, further amplifying
neurogenic inflammation. Advanced imaging techniques, such as diffusion
tensor imaging and voxel-based morphometry, have revealed structural and
functional alterations in white matter tracts, cortical thickness, and pain-
processing regions in chronic migraineurs, suggesting that repeated attacks may
lead to neuroplastic changes that perpetuate the disorder. The role of the blood-
brain barrier in migraines is also under investigation, with evidence suggesting
that increased permeability may facilitate the entry of inflammatory mediators
into the central nervous system, exacerbating neuroinflammation.
The treatment of migraines encompasses a broad spectrum of acute and
preventive strategies, tailored to the patient’s clinical profile, attack frequency,
severity, and comorbidities. Acute treatments aim to rapidly alleviate pain and
associated symptoms, such as nausea, vomiting, photophobia, phonophobia, or
osmophobia. Nonsteroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen,
naproxen, or aspirin, are first-line options for mild to moderate migraines,
offering analgesia through inhibition of cyclooxygenase enzymes and
prostaglandin synthesis. For moderate to severe attacks, triptans (e.g.,
sumatriptan, rizatriptan, zolmitriptan, eletriptan) are the gold standard, acting
via 5-HT1B/1D receptor agonism to constrict dilated cranial blood vessels,
inhibit CGRP release, and reduce trigeminal activation. However, triptans are
contraindicated in patients with cardiovascular risk factors (e.g., hypertension,
coronary artery disease) due to their vasoconstrictive effects. Antiemetics, such
as metoclopramide, ondansetron, or prochlorperazine, are frequently co-
administered to manage nausea and enhance gastric motility, improving oral
drug absorption. For patients with refractory migraines or contraindications to
triptans, newer agents such as ditans (e.g., lasmiditan), which selectively target
5-HT1F receptors without vasoconstrictive effects, and gepants, small-molecule
CGRP receptor antagonists (e.g., rimegepant, ubrogepant, atogepant), have
demonstrated efficacy in aborting attacks with a favorable safety profile. These
SOLUTION OF SOCIAL PROBLEMS IN
MANAGEMENT AND ECONOMY
International scientific-online conference
133
agents represent a paradigm shift in acute migraine management, offering
options for patients previously underserved by conventional therapies.
Preventive treatments are recommended for patients with frequent (more
than four per month), severe, or disabling migraines, or those with significant
medication overuse. Traditional options include beta-blockers (e.g., propranolol,
metoprolol, timolol), which reduce neuronal excitability and sympathetic tone;
anticonvulsants (e.g., topiramate, valproate, gabapentin), which modulate
GABAergic and glutamatergic signaling; and tricyclic antidepressants (e.g.,
amitriptyline, nortriptyline), which enhance descending pain inhibition and
regulate serotonin and norepinephrine levels. Calcium channel blockers (e.g.,
flunarizine, verapamil) and angiotensin receptor blockers (e.g., candesartan) are
also used in some regions, though their mechanisms in migraine prevention are
less well elucidated. Botulinum toxin type A (onabotulinumtoxinA) is an
established preventive therapy for chronic migraines, acting by inhibiting the
release of pain-mediating neurotransmitters such as CGRP and substance P at
peripheral nerve endings. The advent of CGRP-targeted therapies has
revolutionized preventive management. Monoclonal antibodies targeting CGRP
or its receptor (e.g., erenumab, fremanezumab, galcanezumab, eptinezumab)
have demonstrated robust efficacy in reducing migraine frequency, severity, and
medication overuse in clinical trials, with response rates of 50-70% in treated
populations. These biologics, administered monthly or quarterly via
subcutaneous or intravenous routes, are particularly beneficial for patients with
chronic migraines or those refractory to traditional therapies. Their high
specificity and minimal side effects, such as injection-site reactions or mild
constipation, mark a significant advancement, though long-term safety data,
particularly regarding cardiovascular, hepatic, and immunological effects, are
still being evaluated.
Non-pharmacological interventions are integral to comprehensive migraine
management, addressing both trigger mitigation and symptom control.
Cognitive-behavioral therapy (CBT), biofeedback, and mindfulness-based stress
reduction help patients manage stress, a common trigger, and develop coping
strategies to reduce attack frequency and severity. Progressive muscle
relaxation, guided imagery, and autogenic training can further mitigate
autonomic arousal and enhance relaxation. Lifestyle modifications, including
consistent sleep hygiene, regular physical activity, adequate hydration, and
avoidance of dietary triggers, are critical for minimizing susceptibility. Dietary
interventions, such as ketogenic, low-glycemic, or low-tyramine diets, are under
SOLUTION OF SOCIAL PROBLEMS IN
MANAGEMENT AND ECONOMY
International scientific-online conference
134
investigation for their potential to modulate neuroinflammation, neuronal
excitability, and mitochondrial function. Neuromodulation devices have
emerged as promising adjuncts, offering non-invasive or minimally invasive
options for both acute and preventive treatment. Transcutaneous supraorbital
nerve stimulation (tSNS), single-pulse transcranial magnetic stimulation (sTMS),
and non-invasive vagus nerve stimulation (nVNS) modulate cortical excitability
and pain signaling, with clinical trials demonstrating reductions in attack
frequency, severity, and acute medication use. Remote electrical
neuromodulation (REN), a novel device targeting conditioned pain modulation,
has shown efficacy in acute treatment, particularly for patients seeking drug-
free options or those with contraindications to pharmacotherapy.
Emerging research is uncovering novel therapeutic targets that promise to
further transform migraine management. The hypothalamus, implicated in
attack initiation, is a focus of investigation, with studies exploring its role in
regulating circadian rhythms, autonomic responses, and neuroendocrine
signaling. Neuropeptides beyond CGRP, such as pituitary adenylate cyclase-
activating polypeptide (PACAP), vasoactive intestinal peptide (VIP), and
neuropeptide Y, are under scrutiny for their roles in neurogenic inflammation
and vasodilation, with early-phase trials of PACAP antagonists showing promise
in reducing migraine frequency. The role of the gut-brain axis is gaining
significant traction, with preliminary studies suggesting that probiotics,
prebiotics, or fecal microbiota transplantation may reduce migraine frequency
by modulating systemic inflammation, neurotransmitter production, and gut
barrier integrity. Pharmacogenomics is another frontier, with potential to tailor
treatments based on individual genetic profiles, improving response rates and
minimizing adverse effects. For example, polymorphisms in CGRP-related genes,
serotonin receptors, or drug-metabolizing enzymes (e.g., CYP450) may predict
responsiveness to CGRP-targeted therapies or triptans. Neuroinflammatory
pathways, including microglial activation, cytokine signaling, and toll-like
receptor activation, are also being explored, with potential for anti-
inflammatory agents, glial modulators, or interleukin inhibitors to serve as
adjunctive therapies. The role of oxidative stress and mitochondrial dysfunction
in migraines is another emerging area, with studies suggesting that antioxidants
(e.g., coenzyme Q10, riboflavin) or mitochondrial-targeted therapies may reduce
neuronal excitability and attack frequency.
Despite these advancements, significant challenges remain in migraine
management. The heterogeneity of the disorder complicates diagnosis and
SOLUTION OF SOCIAL PROBLEMS IN
MANAGEMENT AND ECONOMY
International scientific-online conference
135
treatment, as patients exhibit diverse trigger profiles, symptom patterns, and
treatment responses. Access to novel therapies, particularly CGRP inhibitors and
neuromodulation devices, is limited by high costs, variable insurance coverage,
and regulatory barriers, particularly in low- and middle-income countries. This
disparity exacerbates the global burden of migraines, which disproportionately
affects underserved populations, including women, rural communities, and
those with limited healthcare access. The long-term safety of newer agents, such
as CGRP monoclonal antibodies and gepants, requires ongoing surveillance,
particularly regarding potential cardiovascular, hepatic, renal, or immunological
effects. Medication overuse headache, a common complication of frequent acute
treatment, remains a significant clinical challenge, necessitating careful patient
education, monitoring, and structured withdrawal protocols. Furthermore, the
psychological and social dimensions of migraines, including stigma, social
isolation, and mental health comorbidities (e.g., anxiety, depression, post-
traumatic stress disorder), are often underaddressed, highlighting the need for
integrated care models that combine neurological, psychological, and social
interventions.
The global burden of migraines underscores the urgency of public health
initiatives to improve awareness, diagnosis, and access to care. Migraine is a
leading cause of disability worldwide, particularly among women of working
age, yet it remains underdiagnosed and undertreated in many regions.
Educational campaigns targeting healthcare providers, patients, and the public
can enhance early recognition, reduce diagnostic delays, and promote evidence-
based management. Policy efforts to reduce treatment costs, expand insurance
coverage, and integrate novel therapies into healthcare systems are critical for
addressing disparities. Multidisciplinary care models, incorporating
neurologists, pain specialists, psychologists, nutritionists, and physical
therapists, are essential for addressing the multifaceted nature of the disorder.
Patient advocacy groups and international organizations, such as the
International Headache Society and the World Health Organization, play a vital
role in amplifying the voices of those affected, driving research priorities, and
advocating for policy changes to improve access to care.
In conclusion, migraines are a complex neurological disorder driven by a
dynamic
interplay
of
genetic,
environmental,
neurovascular,
neuroinflammatory, and neuroendocrine mechanisms. Advances in
understanding the roles of CGRP, cortical spreading depression, serotonin
dysregulation,
hypothalamic
activation,
the
gut-brain
axis,
and
SOLUTION OF SOCIAL PROBLEMS IN
MANAGEMENT AND ECONOMY
International scientific-online conference
136
neuroinflammatory pathways have ushered in a new era of targeted therapies,
complemented by established pharmacological and non-pharmacological
approaches. Emerging research into novel pathways, precision medicine, and
integrative interventions holds promise for further improving outcomes and
reducing the global burden of migraines. However, addressing this burden
requires concerted efforts to enhance access, reduce disparities, and integrate
multidisciplinary care. By bridging the gap between scientific discovery, clinical
application, and public health policy, the field can move closer to alleviating the
profound impact of migraines on individuals and society, paving the way for
more effective, equitable, and personalized management strategies.
References:
1. Goadsby, P. J., Holland, P. R., Martins-Oliveira, M., Hoffmann, J., Schankin, C., &
Akerman, S. (2017). Pathophysiology of migraine: A disorder of sensory
processing. Physiological Reviews, 97(2), 553-622.
2. Charles, A., & Brennan, K. C. (2010). Cortical spreading depression—new
insights and persistent questions. Cephalalgia, 30(9), 1113-1120.
3. Dodick, D. W. (2018). Migraine. The Lancet, 391(10127), 1315-1330.
4. Lipton, R. B., Bigal, M. E., Diamond, M., Freitag, F., Reed, M. L., & Stewart, W. F.
(2007). Migraine prevalence, disease burden, and the need for preventive
therapy. Neurology, 68(5), 343-349.
5. Burstein, R., Noseda, R., & Borsook, D. (2015). Migraine: Multiple processes,
complex pathophysiology. Journal of Neuroscience, 35(17), 6619-6629.
6. Ashina, M., Hansen, J. M., Do, T. P., Melo-Carrillo, A., Burstein, R., & Moskowitz,
M. A. (2019). Migraine and the trigeminovascular system—40 years and
counting. The Lancet Neurology, 18(8), 795-804.
7. Edvinsson, L., Haanes, K. A., Warfvinge, K., & Krause, D. N. (2018). CGRP as the
target of new migraine therapies—successful translation from bench to clinic.
Nature Reviews Neurology, 14(6), 338-350.
8. Russo, A. F. (2015). Calcitonin gene-related peptide (CGRP): A new target for
migraine. Annual Review of Pharmacology and Toxicology, 55, 533-552.
9. Arumugam, M., & Parthasarathy, V. (2020). Gut-brain axis and migraine: The
role of microbiota in neuroinflammation. Journal of Neuroimmunology, 347,
577345.
10. Silberstein, S. D., Holland, S., Freitag, F., Dodick, D. W., Argoff, C., & Ashman, E.
(2012). Evidence-based guideline update: Pharmacologic treatment for episodic
migraine prevention in adults. Neurology, 78(17), 1337-1345.
11. Starling, A. J., & Dodick, D. W. (2019). Advances in migraine management:
Focus on CGRP-targeting therapies. Neurology, 92(17), 791-800.
SOLUTION OF SOCIAL PROBLEMS IN
MANAGEMENT AND ECONOMY
International scientific-online conference
137
12. Puledda, F., Shields, K., & Goadsby, P. J. (2020). Neuromodulation for the
acute and preventive treatment of migraine. Current Opinion in Neurology,
33(3), 347-353.
13. Buse, D. C., Greisman, J. D., Baigi, K., & Lipton, R. B. (2019). Migraine-related
disability, impact, and health-related quality of life among patients with
migraine. Headache, 59(1), 86-100.
14. Schwedt, T. J., & Chong, C. D. (2015). Functional imaging and migraine: New
connections? Current Opinion in Neurology, 28(3), 249-257.
15. Headache Classification Committee of the International Headache Society
(IHS). (2018). The International Classification of Headache Disorders, 3rd
edition. Cephalalgia, 38(1), 1-211.
